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Background: Asthma exacerbations are frequent in patients with severe disease. This report describes results from
two retrospective cohort studies describing exacerbation frequency and risk, emergency department (ED)/hospital
re-admissions, and asthma-related costs by asthma severity in the US and UK.
Methods: Patients with asthma in the US-based Clinformatics™ DataMart Multiplan IMPACT (2010–2011; WEUSKOP7048)
and the UK-based Clinical Practice Research Datalink (2009–2011; WEUSKOP7092) databases were categorized by disease
severity (Global Initiative for Asthma [GINA]; Step and exacerbation history) during the 12 months pre-asthma medical
code (index date). Outcomes included: frequency of exacerbations (asthma-related ED visit, hospitalization, or oral
corticosteroid use with an asthma medical code recorded within ±2 weeks) 12 months post-index, asthma-related ED
visits/hospitalization, and asthma-related costs 30 days post-index. Risk of a subsequent exacerbation was determined by
proportional hazard model.
Results: Of the 222,817 and 211,807 patients with asthma included from the US and UK databases, respectively,
12.5 and 8.4% experienced ≥1 exacerbation during the follow-up period. Exacerbation frequency increased with
disease severity. Among the 5,167 and 2,904 patients with an asthma-related ED visit/hospitalization in the US
and UK databases, respectively, 9.2 and 4.7% had asthma-related re-admissions within 30 days. Asthma-related
re-admission rates and costs increased with disease severity, approximately doubling between GINA Step 1 and
5 and in patients with ≥2 versus <2 exacerbations in the previous year. Risk of a subsequent exacerbation
increased 32–35% for an exacerbation requiring ED visit/hospitalization versus oral corticosteroids.
Conclusion: Increased disease severity was associated with higher exacerbation frequency, ED/hospitalization
re-admission, costs and risk of subsequent exacerbation, indicating that these patients require high-intensity
post-exacerbation management.
Keywords: Exacerbation, Healthcare utilization, Electronic medical records, Claims database, Severe uncontrolled
asthma, Severe eosinophilic asthmaBackground
Worldwide, 235 million people are estimated to suffer
from asthma, [1] affecting 1–18% of the population in dif-
ferent countries [2]. Asthma is characterized by symptoms
such as wheeze, chest tightness and shortness of breath,
which can vary in intensity over time [2]. Exacerbations of
asthma are acute or sub-acute episodes of increased* Correspondence: frank.c.albers@gsk.com
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(http://creativecommons.org/publicdomain/zesymptoms and deteriorations in lung function, requiring
an intensification of treatment [2]. Exacerbations occur
across the spectrum of asthma severity but are more fre-
quent in patients with severe disease and place a great
burden on healthcare systems and patients [2–4].
Guidelines highlight the importance of using preventa-
tive therapies to reduce the risk and frequency of asthma
exacerbations [2]. In patients with mild-to-moderate
asthma, exacerbation frequency can be reduced by main-
tenance controller therapies such as inhaled corticoste-
roids (ICS) combined with long-acting β2-agonists (LABA)le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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persistent symptoms, a 5-year study has shown that
exacerbation frequency remains relatively unchanged, des-
pite intensive therapy with ICS/LABA for a minimum of
4 months per year [9]. Small-scale observational and data-
base studies have demonstrated that the risk of a subse-
quent exacerbation is increased in patients with a history
of frequent events and in patients with eosinophilic inflam-
mation [9–11]. Healthcare resource utilization (HRU) is
reported to be greatest in patients with severe asthma and
a history of previous exacerbations, with exacerbations
requiring oral corticosteroid (OCS) treatment, and
emergency department (ED) visits or hospitalization docu-
mented as posing the greatest burden to healthcare
systems [2, 12–15]. Additionally, the average direct costs
per patient are reported to be approximately twice as high
in patients with severe uncontrolled asthma compared
with those that have non-severe uncontrolled asthma [16].
To improve disease management, there is a need to
better characterize the burden of asthma exacerbations
by disease severity. This report describes the results
from two large retrospective cohort studies from the
US and UK, which aimed to characterize the overall
asthma exacerbation rates, their subsequent reoccur-
rence, associated HRU, and costs by asthma severity.
Methods
Study design
This report presents the results of two retrospective co-
hort studies of patients with asthma. The US study (GSK
ID: WEUSKOP7048) identified patients from the US-
based Clinformatics™ DataMart Multiplan (IMPACT)
database (OptumInsight Life Sciences Inc., Eden Prairie,
MN) (January 1, 2010–December 31, 2011). The UK study
(GSK ID: WEUSKOP7092) identified patients from the
UK-based Clinical Practice Research Datalink (CPRD;
January 1, 2009–December 31, 2011). The index date
was defined as the date of the first recorded asthma
medical code during the study periods. In both data-
bases, asthma severity and exacerbation history were
determined during the 3-month and 12-month pe-
riods, respectively, prior to and including the study
index date. During the 12-month period following
asthma index date, the occurrence of exacerbations,
medication use, and HRU associated with asthma
exacerbations were determined in both the US and
UK. Healthcare cost associated with asthma exacerba-
tions was determined in the US only.
Patients
Patients were identified in respective US and UK data-
bases using the following inclusion criteria: ≥12 years of
age, an asthma medical code (US: International Classifi-
cation of Diseases, 9th Revision: 493.xx; UK: CPRDmedical codes/Read codes) during the study period; at
least one asthma medication (short-acting β2-agonists
[SABA], short-acting muscarinic antagonist [USA only],
ICS, ICS/LABA combination products, leukotriene
receptor antagonist [LTRA], mast cell stabilizers, meth-
ylxanthines, or anticholinergics [long-acting muscarinic
antagonist]) prescribed during the 3 months (US) or
30 days (UK) prior to the index date (inclusive); enroll-
ment in respective databases for the 12 months before
and after the index date. Exclusion criteria in both data-
bases were: patients with a chronic obstructive pulmon-
ary disease or cystic fibrosis diagnosis. In the US
database, patients with a diagnosis for lung cancer were
also excluded. Where available, UK database patient
records in the CPRD were linked to the Hospital Epi-
sode Statistics (HES) data warehouse, containing
records of all National Health Service hospital admis-
sions and outpatient appointments.Outcomes and assessments
The frequency of ≥1 or ≥2 exacerbations in patients and
the mean annual asthma exacerbation rate was assessed
during the 12 months after the index date. Exacerbations
were defined as a worsening of asthma requiring an ED/
hospital admission or OCS treatment (US study: any OCS
use equivalent to 20 mg/day prednisone for 3–28 days
with an asthma medical code recorded within 2 weeks of
the OCS prescription; UK: any OCS prescription within
2 weeks of an asthma medical code).
Exacerbations occurring within 7 days of the end date of
an OCS prescription, ED admission, hospital discharge, or
HES spell (healthcare episodes where a patient may have
received care under more than one consultant within a
hospital provider; UK only) were considered part of the
same exacerbation [17]. Total all-cause and asthma-
related ED/hospital re-admissions during the 30-, 60- and
90-day periods following a previous index asthma-related
ED/hospital admission were also determined. The fre-
quency of total HRU (US: inpatient admissions, ED visits,
physician office visits, and other outpatient visits; UK: hos-
pital admissions recorded by HES linked to CPRD, ED
visits, general practice surgery visits, nurse visits, and tele-
phone calls) was assessed during the 30-day period after an
exacerbation. Asthma medication utilization (SABA, LTRA,
ICS, ICS/LABA, OCS, anti-immunoglobulin E therapy
[omalizumab], and theophylline and its derivatives]) during
the 45-day period prior (to allow for gaps in prescriptions)
and 30-day period after an asthma exacerbation was also
assessed (non-mutually-exclusive categories). In the US
study only, total-related costs (pharmacy, laboratory, and
medical) and asthma-related costs (inpatient admissions,
ED visits, outpatient visits, and pharmacy/medication
costs) were determined from standardized insurance
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(inclusive) after an exacerbation.
Covariates
Covariates assessed as potential confounders during the
pre-index period included asthma severity, patient demo-
graphics (age, gender, atopic status) and exacerbation his-
tory. Asthma severity was assessed by medication use
during the 90 days before the index date and categorized by
Global Initiative for Asthma (GINA) or British Thoracic So-
ciety (BTS) Step in accordance with respective guidelines
[2, 18]; separate medications were required to have a start
date within 30 days of each other to be considered part of
the same treatment regimen. Severity was also categorized
by OCS and SABA prescription fills during the 12-month
pre-index period, assessed by the modified Leidy category
as defined by Wells et al. (2012) [2, 19]. Exacerbation his-
tory was determined from the 12-month period before the
index date and presented as a categorical variable (number
of exacerbations: 0, 1, 2, 3, ≥4) and binary variable (<2 or
≥2 exacerbations). Patients with ‘severe uncontrolled
asthma’ were defined as patients at GINA Step 4 or 5 with
≥2 exacerbations in the previous 12 months. Patients with
‘severe uncontrolled eosinophilic asthma’ were defined as
fulfilling the criteria for ‘severe uncontrolled asthma’ and
had blood eosinophil counts ≥300 cells/μl at baseline.
Atopic status was determined by the presence of an allergic
rhinitis medical code during the baseline period. Exacerba-
tion season was determined as: spring (March–May), sum-
mer (June–August), fall (September–November), and
winter (December–February).
Statistical analysis
Demographic characteristics were reported as count (%) for
categorical variables and mean (standard deviation) for con-
tinuous variables. Mean annual asthma exacerbation rates
were calculated using a simple unadjusted negative binomial
regression model and described with 95% confidence inter-
vals. The association between the severity of asthma exacer-
bations and the risk of subsequent exacerbations was
analyzed using a multi-variable Cox regression model, in-
corporating covariates with a p-value >0.10 and potential
confounder variables with a p-value <0.10. Age, gender,
asthma severity, and exacerbation history were also in-
cluded. For ICS claims where the number of days treatment
supply was missing or was <15 days, a value of 30 days was
imputed; for ICS/LABA, LTRA or methylxanthines claims
where supply length was missing or <30 days, a value of
30 days was imputed.
Results
Patients
In total, data from 222,817 and 211,807 patients in the
US and UK databases, respectively, were included in thestudy (Table 1). Overall, patients in the US had a lower
average age than the UK. During the pre-index period,
patients in the US were less likely to be classified at
GINA Step 4/5 (moderate severe) and had a higher
mean annual exacerbation rate compared with the UK.
During the 12-month follow-up period, 27,865 (12.5%)
and 5,560 (2.5%) patients in the US, and 17,785 (8.4%)
and 3,592 (1.7%) of patients in the UK experienced ≥1
and ≥2 exacerbations, respectively (Table 1). Compared
with patients with ≥1 exacerbations, patients with ≥2 ex-
acerbations tended to have more severe disease defined
as higher GINA Step, a history of more frequent exacer-
bations or severe uncontrolled and severe uncontrolled
eosinophilic asthma (Table 1). Further patient details are
available in Additional file 1: Table S1.
Exacerbation frequency
The overall mean annual exacerbation rates per patient dur-
ing the 12-month period after the index date in the US and
UK were 0.16/year and 0.11/year, respectively (Table 2).
Mean annual exacerbation frequency increased with indica-
tors of disease severity (GINA Step, severe uncontrolled and
uncontrolled eosinophilic asthma status) and with historical
exacerbation frequency (Table 2; Fig. 1a–c). Exacerbations
were more frequent in females, in atopic patients, and their
frequency increased with Leidy category (Additional file 1:
Table S2). Mean annual exacerbation rate trends during the
12-month follow-up period were broadly consistent across
covariates in both the US and UK, although overall mean
annual exacerbation rates were higher in the US.
Risk of a subsequent asthma exacerbation
In an adjusted proportional hazard model, patients who ex-
perienced an exacerbation requiring an ED/hospital admis-
sion had a 35 and 32% greater risk of a subsequent
exacerbation during the 12 months after the index date
compared with patients experiencing exacerbations only re-
quiring OCS in the US and UK, respectively (Table 3). Pa-
tients with the most severe disease as assessed by GINA
(US) or BTS (UK) Step demonstrated the highest risk of a
subsequent exacerbation during the 12 months after the
index date. In particular, the adjusted risk of a subsequent
exacerbation was increased by 44% for patients at GINA
Step 5 compared with at Step 1–3 (US) and by 87% at BTS
Step 5 versus Step 1 (UK). Other factors associated with an
increased risk of a subsequent exacerbation were ≥1 exacer-
bation in the previous year (assessed in the UK only)
(Table 3), female gender, a higher Leidy category, and atopic
status (assessed in the UK only) (Additional file 1: Table S3).
HRU
ED/hospital re-admission
In the 30-day period following discharge for an asthma-
related ED/hospital visit, asthma-related ED/hospital
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Table 2 Mean annual exacerbation rate per patient year in the 12 months post-index date by covariate
US database
(N = 222,817)
Rate (95% CI)
UK database
(N = 211,807)
Rate (95% CI)
Overall 0.161 (0.159, 0.163) 0.110 (0.109, 0.111)
GINA Step Step 1 0.139 (0.136, 0.142) 0.066 (0.063, 0.069)
Step 2 0.143 (0.138, 0.147) 0.070 (0.067, 0.073)
Step 3 0.153 (0.148, 0.158) 0.086 (0.084, 0.089)
Step 4 0.186 (0.181, 0.191) 0.126 (0.123, 0.130)
Step 5 0.455 (0.434, 0.478) 0.512 (0.490, 0.536)
Not classifiable/none 0.105 (0.078, 0.142) 0.113 (0.084, 0.150)
Exacerbations during the 12-month pre-index period 0 0.110 (0.109, 0.112) 0.070 (0.069, 0.071)
1 0.308 (0.301, 0.315) 0.273 (0.265, 0.282)
2 0.674 (0.638, 0.712) 0.644 (0.601, 0.690)
3 1.150 (1.036, 1.276) 1.236 (1.080, 1.414)
≥4 2.195 (1.925, 2.504) 2.687 (2.269, 3.183)
Severe uncontrolled asthmaa Yes 1.016 (0.939, 1.099) 1.088 (1.002, 1.181)
No 0.153 (0.151, 0.155) 0.098 (0.096, 0.100)
Severe uncontrolled eosinophilic asthmab Yes 1.158 (0.828, 1.619) 1.389 (1.127, 1.712)
No 0.153 (0.148, 0.159) 0.132 (0.128, 0.136)
aDefined as patients at GINA Step 4 or 5 with ≥2 exacerbations in the previous 12 months; bpatients with severe uncontrolled asthma criteria and blood
eosinophil counts ≥300 cells/μl at baseline. CI confidence interval, GINA Global Initiative for Asthma
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all-cause ED/hospital re-admissions occurred in 22.6
and 19.1% of patients in the US and UK, respectively.
Both asthma-related and all-cause ED/hospital patient
re-admissions within 30 days were highest in patients
at GINA Step 5 versus Step 1, a history of ≥2 versus <2
exacerbations and severe uncontrolled asthma versus
non-severe asthma. Asthma-related and all-cause re-
admission in patients with severe uncontrolled eosino-
philic asthma versus non-severe asthma were lower in the
US but higher in the UK (Fig. 2a and b; Fig. 3a and b).
Similar trends were seen for the 60- and 90-day periods
(Fig. 2a and b; Fig. 3a and b). Results for ED/hospital re-
admissions by age, gender, Leidy category, and atopic sta-
tus are shown in Additional file 1: Table S4 and S5.
Total HRU after an exacerbation
The overall mean frequency of total HRU during the 30-
day period after an exacerbation was 1.35 and 2.49 inter-
actions/patient in the US and UK, respectively. Total
HRU frequency was highest in patients at GINA Step 5
versus 1 and a history of ≥2 versus <2 exacerbations dur-
ing the pre-index period (Additional file 1: Table S6).
Similarly, the total HRU frequency was higher in
patients with severe uncontrolled asthma, severe uncon-
trolled eosinophilic asthma and with atopic asthma com-
pared with those without (Additional file 1: Table S6).
Additionally, total HRU was similar across age groups in
the US, but increased with age in the UK (Additional file1: Table S6). Overall, the frequency of total HRU was
lower in the US than the UK across all covariates.
Medication HRU before and after an exacerbation
In the 45-day period before an exacerbation, 20.9 and
42.8% of patients received ICS/LABA, and 21.3 and
22.7% of patients received OCS in the US and UK,
respectively. During the 30-day period after an exacer-
bation, the most commonly used medications were
SABAs followed by ICS/LABA and LTRA in the US and
SABAs, ICS/LABA and OCS in the UK (Additional file 1:
Table S7). ICS + LABA and OCS use increased with age
and markers of disease severity including exacerbation
history, severe uncontrolled asthma status, severe uncon-
trolled eosinophilic asthma status, and atopy (Additional
file 1: Table S7). Medication use also increased with GINA
Step and Leidy category, both of which are determined by
medication use. Overall, medication use, including ICS/
LABA and OCS, tended to be lower in the US than the
UK (Additional file 1: Table S7).
Healthcare costs after an exacerbation (assessed in US
database only)
In the US, during the 30-day period after an exacerba-
tion including the index date, the mean all-cause total
insurance provider healthcare cost per exacerbation was
$1,368 (Table 4). Total all-cause costs per exacerbation
increased with disease severity and with a history of ≥2
versus <2 exacerbations/year. Of all the parameters
ab
c
(n = 103,415)(n = 37,438) (n = 36,616)(n = 35,488) (n = 38,497)(n = 78,863) (n = 36,039)(n = 49,169) (n = 7,736) (n = 10,291)
(n = 180,830)(n = 182,712) (n = 36,966)(n = 25,129) (n = 3,758)(n = 2,991) (n = 833) (n = 633) (n = 430) (n = 342)
(n = 220,758) (n = 209,255) (n = 2,059) (n = 2,552) (n = 25,131) (n = 50,089) (n = 114) (n = 357)
GINA Step
Fig. 1 Exacerbation rates during the follow-up period by a GINA category; b exacerbation history, and c severe and severe uncontrolled eosinophilic
asthma. Severe asthma defined as patients at GINA Step 4 or 5 with ≥2 exacerbations in the previous 12 months; Severe eosinophilic asthma defined
as patients with severe uncontrolled asthma criteria and blood eosinophil counts ≥300 cells/μl at baseline. GINA, Global Initiative for Asthma
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uncontrolled eosinophilic asthma, reaching $2,040 per
exacerbation in the 30 days after an exacerbation
including the index date. When the analysis was
restricted to just asthma-related healthcare costs, the
mean total healthcare cost per exacerbation was $520(Table 4). As with all-cause total healthcare cost per
exacerbation, total asthma-related costs increased with
disease severity and in patients a history of ≥2 versus
<2 exacerbations/year and were highest for patients
with severe uncontrolled eosinophilic asthma (Table 4).
Further details of all-cause and asthma-related
Table 3 Risk of a subsequent exacerbation of patients with ≥1 exacerbation during the 12-month after a previous exacerbation
US database UK database
N = 27,865 N = 17,785
Covariates HR (95% CI)a HR (95% CI)b
Exacerbation type OCS only Ref. Ref.
ED/hospitalization 1.35 (1.26, 1.44) 1.32 (1.18, 1.47)*
Exacerbations during the 12-month pre-index period 0 NR Ref.
≥1 NR 1.90 (1.75, 2.05)*
GINA (US only) or BTS (UK only) Treatment Stepsc Step 1 Steps 1–3 combined: Ref. Ref.
Step 2 1.02 (0.90, 1.17)
Step 3 1.35 (1.19, 1.53)*
Step 4 1.26 (1.18, 1.35) 1.44 (1.25, 1.65)*
Step 5 1.44 (1.32, 1.56) 1.87 (1.64, 2.14)*
Not classifiable/none 0.76 (0.34, 1.69) 1.36 (0.85, 2.19)
*p < 0.0001
aMultivariable proportional hazards model with the following covariates: exacerbation type, gender, GINA Step, Leidy category
bmultivariable proportional hazards model with the following covariates: exacerbation type, gender, BTS Step, atopy, Leidy category and exacerbation history;
cGINA failed the proportionality test so was removed from the UK database
BTS British Thoracic Society, CI confidence interval, ED emergency department, GINA Global Initiative for Asthma, HR hazard ratio, NR not referenced,
OCS oral corticosteroids
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S8 and S9.
Discussion
In this report of two large database studies in the US
and UK, each involving >200,000 patients with asthma,
it was demonstrated that increased disease severity de-
fined by GINA Step, medication use, and exacerbation
history was associated with higher asthma exacerbation
frequency. Furthermore, patients with an asthma-related
exacerbation leading to ED/hospital re-admission had a
32–35% increased risk of a subsequent exacerbation dur-
ing the 12 months after the index date in both countries
and healthcare resource use within 30 days of an exacer-
bation was highest for patients with the most severe dis-
ease. While overall trends were similar between the US
and UK, US patients demonstrated a higher exacerbation
frequency, lower medication use, and higher ED/hospital
re-admission rates compared with UK patients.
The trends demonstrated in both the US and UK are
similar to previous studies. The smaller-scale TENOR
study demonstrated that exacerbation frequency was
higher in patients who had a recent history of an exacer-
bation compared with those who did not [10]. In a study
of health insurance claims from approximately 2,500 pa-
tients with persistent asthma, the occurrence of an ex-
acerbation in the previous year was found to increase
the risk of a subsequent exacerbation nearly 8-fold [9].
Exacerbation severity has also been shown to increase
subsequent exacerbation risk. The TENOR study dem-
onstrated that the occurrence of a recent severe exacer-
bation requiring an ED/hospital admission increased theodds of a future exacerbation nearly 3-fold following ad-
justment for key covariates, compared with patients with
exacerbations not requiring admissions [10]. In the
current large database studies, following adjustment for
confounding covariates, the risk of a subsequent exacer-
bation during the following year was increased by 35%
(US) and 32% (UK) in patients who had a previous ex-
acerbation requiring an ED/hospital visit compared with
patients requiring only OCS treatment. Exacerbation risk
has also been demonstrated to increase with eosinophilia
[11]. Although in the current study eosinophil counts
were not assessed as a risk factor, it was demonstrated
that the proportion of patients experiencing ≥1 exacer-
bations during the follow-up period was higher in
patients who had severe uncontrolled asthma (GINA
Step 4/5 plus ≥2 exacerbations in the previous year) with
eosinophil counts (≥300 cells/μl) than in patients who
did not. The current study also demonstrated that fe-
males had a higher exacerbation risk than males, a result
demonstrated in a previous study, [20] although not all
studies are in agreement [21].
As expected, in both countries, the use of ICS/LABA
and OCS increased with markers of disease severity in-
cluding GINA Step, Leidy category, and exacerbation
history, and was higher in patients with severe uncon-
trolled asthma or severe uncontrolled eosinophilic
asthma status versus patients who had non-severe
asthma. In the current study, despite the increased
medication usage in patients with more severe disease,
total HRU during the 30 days after an exacerbation was
still highest in these patients. Reflecting this, a previous
study demonstrated in patients with persistent asthma
ab
≥
(n = 5,167) (n = 2,482) (n = 719) (n = 784)
GINA Step
GINA Step
(n = 832) (n = 342) (n = 4,536) (n = 631) (n = 4,943) (n = 244) (n = 552) (n = 9)
(n = 2,904) (n = 404) (n = 373) (n = 849) (n = 797) (n = 475) (n = 2,439) (n = 465) (n = 2,572) (n = 332) (n = 742) (n = 45)
Fig. 2 Proportion of patients with an asthma-related ED/hospital re-admission after being discharged for an asthma-related ED/hospital admission
within the a US database and b UK database. Severe asthma defined as patients at GINA Step 4 or 5 with ≥2 exacerbations in the previous
12 months; Severe eosinophilic asthma defined as patients with severe uncontrolled asthma criteria and blood eosinophil counts ≥300 cells/μl at
baseline. ED, emergency department; GINA, Global Initiative for Asthma
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number of asthma exacerbations over a 5-year period
remained relatively unchanged [9]. Most strikingly, the
proportion of patients with asthma-related ED/hospital
re-admissions in the 30-day period following a previous
ED/hospital admission approximately doubled between
GINA Step 3 and Step 5. Similarly, a history of frequent
exacerbations and a severe disease classification in-
creased asthma-related re-admission rates, with up to
23% experiencing an asthma-related re-admission
within 30 days of discharge. These trends are reflected
in a previous small-scale US-based study, which dem-
onstrated that the majority of ED visits were made by
the most severe patients (≥6 ED visits in the previous
year) and that markers of severity were independent
predictors of high ED use [14]. Together, these results
indicate that patients with severe disease are the most
likely to require further healthcare utilization after anasthma exacerbation, suggesting that higher levels of
step-up care and the use of novel drug classes may be
needed [22].
In terms of healthcare costs in the US during the
30 days after an exacerbation, asthma-related costs
were higher in patients with a greater history of exacer-
bations and categorized as having severe uncontrolled
asthma or severe uncontrolled eosinophilic asthma
compared with patients who did not meet these cri-
teria. Specifically, patients with severe uncontrolled eo-
sinophilic asthma, the asthma-related cost was $1,073
compared with $520 in the overall asthma population
during the 30 days after an exacerbation. Similarly, an
observational study by Zeiger et al. (2015) demon-
strated that the annual asthma-related costs approxi-
mately doubled in patients with severe uncontrolled
asthma compared with patients with non-severe uncon-
trolled asthma [16]. Broadly, the results of both studies
ab
History of exacerbations
History of exacerbations
≥
(n = 5,167) (n = 2,482) (n = 719) (n = 784)
GINA Step
GINA Step
(n = 832) (n = 342) (n = 4,536) (n = 631) (n = 4,943) (n = 244) (n = 552) (n = 9)
(n = 2,904) (n = 404) (n = 373) (n = 849) (n = 797) (n = 475) (n = 2,439) (n = 465) (n = 2,572) (n = 332) (n = 742) (n = 45)
Fig. 3 Proportion of patients with an all-cause ED/hospital re-admission following an index asthma-related ED/hospital admission within the a US
database and b UK database. Severe asthma defined as patients at GINA Step 4 or 5 with ≥2 exacerbations in the previous 12 months; Severe eosino-
philic asthma defined as patients with severe uncontrolled asthma criteria and blood eosinophil counts ≥300 cells/μl at baseline. ED, emergency de-
partment; GINA, Global Initiative for Asthma
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scale population studies [15].
Whilst the overall trends in both databases were simi-
lar, some differences were identified between the US and
UK. In the UK, the exacerbation frequency for patients
at GINA Step 1–3 was approximately half that of the
US, despite the frequency of exacerbations being similar
between the UK and US for GINA Step 4–5. This may
be a reflection of the higher ICS/LABA and OCS use at
these lower treatment steps in the UK compared with
the US, since ICS/LABA use has been demonstrated to
decrease exacerbation frequency [2, 5]. Asthma-related
ED/hospital re-admission within 30 days was also higher
in the US compared with the UK, which could also be
related to medication use or differences in the access to
primary care physicians in these countries.
The strength of these studies is that they sample data
from a large number of patients (>400,000 across theUS and UK), allowing for the characterization of
exacerbation frequency and HRU across a wide range
of asthma severities and provide insights into the differ-
ences between the two populations. However, there are
also several limitations, some inherent to the retro-
spective database methodology. Disease severity was
inferred by GINA or BTS Step rather than clinical
measurements, which may have led to severity being
incorrectly assigned due to fluctuations in physician
prescribing behavior over time. Limitations that affect
database comparability include differences in the type
of data that the US (prescription claims) and UK (medi-
cation prescriptions) databases use, which may have led
to an underestimated or overestimated medication use.
In the US specifically, this may have contributed to an
under-reporting of SABA use, as patients may not have
required a new SABA prescription if the previous one
had not been completely used. Further limitations that
Table 4 Mean healthcare cost per exacerbation in the 30 days after an exacerbation (US database only)
Total all-cause ($) Total asthma-related ($)
mean (SD) mean (SD)
Overall 1,368 (3,797) 520 (981)
GINA Step Step 1 1,265 (3,981) 446 (908)
Step 2 1,376 (3,978) 465 (874)
Step 3 1,253 (3,242) 433 (782)
Step 4 1,425 (3,817) 516 (828)
Step 5 1,814 (3,614) 902 (1,533)
Not classifiable/none 946 (1,628) 332 (377)
Exacerbations during the 12-month pre-index period <2 1,344 (3,836) 477 (861)
≥2 1,534 (3,516) 754 (1,451)
Severe uncontrolled asthmaa Yes 1,692 (3,233) 911 (1,563)
No 1,347 (3,831) 486 (905)
Severe uncontrolled eosinophilic asthmab Yes 2,040 (3,285) 1,073 (1,958)
No 1,692 (3,934) 615 (1,248)
aDefined as patients at GINA Step 4 or 5 with ≥2 exacerbations in the previous 12 months; bpatients with severe uncontrolled asthma criteria and blood
eosinophil counts ≥300 cells/μl at baseline
GINA Global Initiative for Asthma, SD standard deviation
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the inclusion of lung cancer as an exclusion criteria in
the US but not UK cohort (these data are not well cap-
tured and recorded in the CPRD); 2) lack of claims data
in the UK CPRD versus US IMPACT database; 3) the
inclusion of only patients with commercial health in-
surance in the US IMPACT versus UK CPRD database
potentially reducing representation of the full asthmatic
population; and 4) UK database patients were not re-
quired to be HES-linked, potentially resulting in the
under-reporting of ED visits and HES spells specific for
the treatment of exacerbations. This may have also pre-
vented the accurate differentiation of exacerbation se-
verity based on ED visit/hospitalization. However, as
BTS and GINA guidelines both recommend treatment
with OCS after ED/hospitalization discharge for an ex-
acerbation, it is likely that most exacerbations were
captured in the data sources sampled.
Conclusions
Using data from >200,000 patients with asthma in both the
US and UK, we demonstrated that the frequency and risk of
asthma exacerbations, HRU, and healthcare costs (US only)
all increased with disease severity. In particular, these out-
comes increased in patients with higher GINA Step, a fre-
quent history of exacerbations, and severe uncontrolled and
severe uncontrolled eosinophilic asthma status. Interestingly,
the results suggest a higher exacerbation frequency, lower
medication use and higher ED/hospital re-admission rates
in the US compared with the UK. Appropriate post-
discharge medication, healthcare practitioner follow-up, and
asthma management plans should be ensured for patientsadmitted to the ED or hospital for asthma. Patients with se-
vere uncontrolled asthma warrant more attentive post-
discharge clinical supervision given their increased risk of a
recurrent ED/hospital re-admission.
Additional file
Additional file 1: Tables S1–S9. Additional results for patient
demographics and baseline characteristics, exacerbation rates,
exacerbation risk, frequency of hospital re-admissions, healthcare
utilization, medication utilization and healthcare costs. (DOC 304 kb)
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